Core Insights - The company reported a total revenue of 4.63 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 11.82% [1] - The revenue from emerging businesses increased by 71.87%, while the revenue from large molecule chemistry grew by over 150% [1] - The net profit attributable to shareholders reached 800 million yuan, marking a year-on-year increase of 12.66% [1] Revenue Breakdown - Revenue from large pharmaceutical companies amounted to 2.05 billion yuan, with a year-on-year growth of 1.98% [1] - Revenue from small and medium-sized pharmaceutical companies was 2.58 billion yuan, reflecting a year-on-year increase of 21.14% [1] Profitability Metrics - The overall gross profit margin for the company was 42.44% for the first three quarters of 2025 [1] - The gross profit margin for small molecule business was 46.99%, remaining stable year-on-year [1] - The gross profit margin for emerging businesses improved by 10.57 percentage points to 30.55%, driven by increased delivery scale and capacity utilization [1] Future Outlook - The company anticipates that the delivery scale in the fourth quarter will significantly exceed that of the third quarter [1] - The company expects an annual revenue growth of 13%-15% for the full year [1]